Paul Swerdlow
Overview
Explore the profile of Paul Swerdlow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jordan L, Swerdlow P, Coates T
J Pediatr Hematol Oncol
. 2013 Mar;
35(3):165-9.
PMID: 23511487
Awareness and practice of appropriate treatment for childhood sickle cell disease (SCD) has improved, and survival rates have increased significantly. Today, most patients will eventually require treatment in the adult-care...
2.
Kutlar A, Meiler S, Swerdlow P, Knight R
Expert Rev Hematol
. 2012 Jan;
5(1):9-11.
PMID: 22272699
No abstract available.
3.
Head C, Swerdlow P, McDade W, Joshi R, Ikuta T, Cooper M, et al.
Am J Hematol
. 2010 Aug;
85(10):800-2.
PMID: 20799359
Pain from vaso-occlusive crisis (VOC) is the major cause of hospitalization in patients with sickle cell disease (SCD). The beneficial therapeutic effects of inhaled nitric oxide (NO) on the pathophysiology...
4.
Steinberg M, Mccarthy W, Castro O, Ballas S, Armstrong F, Smith W, et al.
Am J Hematol
. 2010 Jun;
85(6):403-8.
PMID: 20513116
A randomized, controlled clinical trial established the efficacy and safety of short-term use of hydroxyurea in adult sickle cell anemia. To examine the risks and benefits of long-term hydroxyurea usage,...
5.
Ibrahim R, Liu C, Cronin S, Murphy B, Cha R, Swerdlow P, et al.
J Oncol Pharm Pract
. 2009 Mar;
15(4):217-22.
PMID: 19304881
Cefepime, a fourth generation cephalosporin, is widely used in hematology and oncology patients. These patients may require plasma exchange (PE) for indications such as chemotherapy- or cancer-induced thromobotic thrombocytopenic purpura...
6.
Bao B, Prasad A, Beck F, Snell D, Suneja A, Sarkar F, et al.
Transl Res
. 2008 Aug;
152(2):67-80.
PMID: 18674741
Zinc deficiency is common in adult sickle-cell disease (SCD) patients. We previously demonstrated that zinc supplementation to adult SCD patients decreased the incidences of infections and hospital admissions. We hypothesize...
7.
Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, et al.
Acta Haematol
. 2008 Apr;
119(3):133-41.
PMID: 18408362
Background/aims: There is increasing evidence demonstrating the value of transfusions in sickle cell disease (SCD). However, resultant iron overload can be life threatening if untreated. Chelation therapy with deferoxamine requires...
8.
Ataga K, Smith W, De Castro L, Swerdlow P, Saunthararajah Y, Castro O, et al.
Blood
. 2008 Jan;
111(8):3991-7.
PMID: 18192510
Senicapoc, a novel Gardos channel inhibitor, limits solute and water loss, thereby preserving sickle red blood cell (RBC) hydration. Because hemoglobin S polymerization is profoundly influenced by intracellular hemoglobin concentration,...
9.
Ibrahim R, Liu C, Cronin S, Murphy B, Cha R, Swerdlow P, et al.
Pharmacotherapy
. 2007 Oct;
27(11):1529-49.
PMID: 17963462
Contrary to the literature about drug removal during hemodialysis, data regarding drug removal during plasmapheresis are sparse. Over the last 40 years, approximately 70 publications-mostly case reports of overdoses-have described...
10.
Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, et al.
Br J Haematol
. 2007 Jan;
136(3):501-8.
PMID: 17233848
Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload. Preclinical studies indicated that the kidney was a potential target organ of toxicity. As patients with sickle...